Edgar Filing: PDL BIOPHARMA, INC. - Form 4

PDL BIOPH	IARMA, INC.									
Form 4	07									
April 26, 2006 OMB APPROVAL										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287		
Check tl if no lon subject t Section Form 4	ger o STATEMEN 16. or	NT OF CHAN	SECUR	RITIES					imated average den hours per	
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
Iwanicki David Syn			2. Issuer Name and Ticker or Trading Symbol PDL BIOPHARMA, INC. [PDLI]				5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (Midd		3. Date of Earliest Transaction (Che				(Check	ck all applicable)		
34801 CAN		th/Day/Year)				Director 10% Owner X Officer (give title Other (specify below) VP, Sales & Sales Operations				
	endment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
FREMONT	Г, CA 94555						Form filed by M Person	ore than One Rej	porting	
(City)	(State) (Zip) Tab	le I - Non-I	Derivative	Secu	rities Acqu	iired, Disposed of	, or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	an	ecution Date, if	3. Transactio Code (Instr. 8)	4. Securi on(A) or D (Instr. 3,	ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common			Code V	Amount	(D)	Price	(Instr. 3 and 4)			
Stock	04/24/2006		М	2,187	А	\$ 15.73	2,187	D		
Common Stock	04/24/2006		S <u>(1)</u>	2,187	D	\$ 28.897	0	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: PDL BIOPHARMA, INC. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)1((
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 15.73	04/24/2006		М	2,187	(2)	04/08/2015	Common Stock	2,187

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Iwanicki David 34801 CAMPUS DRIVE FREMONT, CA 94555			VP, Sales & Sales Operations			
Signatures						

/s/ George Jue by George Jue, Attorney in Fact for David Iwanicki

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale was made pursuant to a 10b5-1 plan established by the reporting person.
- (2) Options vest 1/4 on the first anniversary of the vesting date and thereafter vest 1/48 per month. Only vested options are exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

04/26/2006

Date

8 I S